ClinicalTrials.Veeva

Menu
E

Enhancing Care Foundation | Wentworth Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Doravirine
Islatravir
ISL
MK-8591A
DOR

Parent organization

This site is a part of Enhancing Care Foundation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (DOR 100mg) and islatravir (ISL 0.75mg) will be evaluate...

Active, not recruiting
HIV-1 Infection
Drug: MK-8591A

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

Trial sponsors

Merck Sharp & Dohme (MSD) logo
U
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems